Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting
June 06, 2022 16:15 ET
|
Delcath Systems, Inc.
Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response...
AITX's Subsidiary Robotic Assistance Devices Receives Order for AVA and ROSA Security Robots from Romanian Dealer Civitas Group
May 23, 2022 08:40 ET
|
Artificial Intelligence Technology Solutions, Inc.
Detroit, Michigan, May 23, 2022 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (OTCPK:AITX), today announced that its wholly owned subsidiary Robotic Assistance Devices,...
Delcath Systems Reports First Quarter 2022 Results and Provides Business Update
May 10, 2022 07:30 ET
|
Delcath Systems, Inc.
NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
May 09, 2022 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Systems to Host First Quarter 2022 Results
April 28, 2022 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
AITX's Subsidiary Robotic Assistance Launches Significant Upgrade to Analytics Software Suite
April 13, 2022 08:40 ET
|
Artificial Intelligence Technology Solutions, Inc.
Achievements in RAD’s AI Analytics a Boost to the Industry Detroit, Michigan, April 13, 2022 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (OTCPK:AITX), today announced...
Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference
April 08, 2022 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will...
Intrahepatic Cholangiocarcinoma Clinical Trial Pipeline Shows Rapid Progress with 20+ Companies Working to Develop Therapies, Assesses DelveInsight
April 06, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 06, 2022 (GLOBE NEWSWIRE) -- Intrahepatic Cholangiocarcinoma Clinical Trial Pipeline Shows Rapid Progress with 20+ Companies Working to Develop Therapies, Assesses DelveInsight ...
Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference
March 29, 2022 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update
March 25, 2022 07:30 ET
|
Delcath Systems, Inc.
NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...